Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · IEX Real-Time Price · USD
1.970
+0.180 (10.06%)
At close: Mar 28, 2024, 4:00 PM
1.920
-0.050 (-2.54%)
After-hours: Mar 28, 2024, 7:43 PM EDT
Atai Life Sciences Market Cap
Atai Life Sciences has a market cap or net worth of $275.58 million as of March 28, 2024. Its market cap has increased by 35.09% in one year.
Market Cap
275.58M
Enterprise Value
83.25M
1-Year Change
35.09%
Ranking
Category
Stock Price
$1.97
Market Cap Chart
Since the IPO on June 18, 2021, Atai Life Sciences's market cap has decreased from $2.29B to $275.58M, a decrease of -87.96%. That is a compound annual growth rate of -53.36%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 27, 2024 | 297.20M | 3.48% |
Mar 26, 2024 | 287.20M | 4.21% |
Mar 25, 2024 | 275.60M | 1.85% |
Mar 22, 2024 | 270.60M | -2.38% |
Mar 21, 2024 | 277.20M | -1.77% |
Mar 20, 2024 | 282.20M | 1.80% |
Mar 19, 2024 | 277.20M | - |
Mar 18, 2024 | 277.20M | -5.65% |
Mar 15, 2024 | 293.80M | 5.34% |
Mar 14, 2024 | 278.90M | -8.71% |
Mar 13, 2024 | 305.50M | -3.66% |
Mar 12, 2024 | 317.10M | -5.43% |
Mar 11, 2024 | 335.30M | -3.82% |
Mar 8, 2024 | 348.60M | -4.13% |
Mar 7, 2024 | 363.60M | 10.05% |
Mar 6, 2024 | 330.40M | -0.99% |
Mar 5, 2024 | 333.70M | -3.83% |
Mar 4, 2024 | 347.00M | -1.87% |
Mar 1, 2024 | 353.60M | 9.78% |
Feb 29, 2024 | 322.10M | -1.01% |
Feb 28, 2024 | 325.40M | -1.99% |
Feb 27, 2024 | 332.00M | 5.26% |
Feb 26, 2024 | 315.40M | 3.82% |
Feb 23, 2024 | 303.80M | - |
Feb 22, 2024 | 303.80M | -2.66% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Stoke Therapeutics | 290.25M |
Inovio Pharmaceuticals | 289.79M |
ChromaDex | 285.42M |
AC Immune | 280.87M |
XOMA Corporation | 279.02M |
Compass Therapeutics | 271.55M |
EDAP TMS | 271.23M |
Puma Biotechnology | 269.48M |